The verdict
Our read at a glance.
Whether stimulants improve cognitive performance in people who do not have ADHD, as opposed to improving how performing feels.
- The signal
- For diagnosed ADHD the evidence is strong and the approvals are real. The literature on healthy users is the interesting one and it is remarkably consistent: effects on attention, vigilance and subjective motivation are reliable, while effects on complex cognition, learning and creative or open-ended work are small, absent, or negative - and studies repeatedly find that users rate their performance as substantially improved even when measured output did not change. Some work finds the largest gains in the lowest baseline performers and impairment in the highest. Registered trials and reviews continue to examine non-medical use, diversion and misuse patterns.
- The unknown
- What long-term non-prescribed use does to a developing or healthy brain, and how much of the reported benefit is compensation for sleep debt rather than enhancement.
- Our read
- The evidence supports a narrower and more uncomfortable claim than the reputation. It reliably changes how hard work feels, and it does not reliably improve the work. That gap is exactly what makes it so convincing to the person taking it, and it is why self-report is worthless as evidence here.
The mechanism
How it works.
Amphetamine enters presynaptic terminals through the dopamine and noradrenaline transporters, disrupts vesicular storage so transmitter accumulates in the cytoplasm, and then reverses transporter direction so the terminal actively pumps dopamine and noradrenaline out into the synapse. The result is a large, sustained increase in catecholamine signalling, particularly in prefrontal cortex and striatum. In ADHD, where that signalling is insufficient for sustained attention, restoring it improves function - which is why the drug works and why the approvals exist. In someone whose signalling is already adequate, pushing it higher moves them along an inverted-U dose-response curve, where more is not better and can be worse for tasks requiring flexibility. The striatal component is what raises the salience and perceived value of whatever is being done, which explains the reliable finding that tedious work becomes engaging and that users are confident they performed well.
Safety & regulatory boundary
The consequential part.
Approved for ADHD and narcolepsy; Schedule II in the United States, which means non-prescribed possession is a felony-level matter and diversion is prosecuted. Labels carry a boxed warning on abuse, misuse and dependence. Cardiovascular effects include raised blood pressure and heart rate with reported serious events, and psychiatric effects include psychosis, mania and, on withdrawal, marked depression. Prohibited in sport in competition.
What's next
What we're watching.
Long-term outcome data in non-prescribed users, and whether the effort-perception framing displaces the enhancement framing in the literature.
Context
Why this is discussed.
It is the most widely diverted prescription drug on university campuses and in high-pressure workplaces, and the belief that it makes you smarter is close to universal among people using it that way.
The evidence base
23 cited references.
Regulatory & labels3
SpecGx LLC (FDA label) · 2023
Bryant Ranch Prepack (FDA label) · 2024
Elite Laboratories, Inc. (FDA label) · 2026
Registered trials8
ClinicalTrials.gov · PHASE2 · RECRUITING · 2026-06-03
ClinicalTrials.gov · EARLY_PHASE1 · COMPLETED · 2023-12-20
ClinicalTrials.gov · NA · COMPLETED · 2017-10-13
ClinicalTrials.gov · PHASE2/PHASE3 · COMPLETED · 2022-01-02
ClinicalTrials.gov · EARLY_PHASE1 · COMPLETED · 2024-08-01
ClinicalTrials.gov · NA · RECRUITING · 2025-01-01
ClinicalTrials.gov · PHASE2 · RECRUITING · 2026-01-30
ClinicalTrials.gov · PHASE2 · RECRUITING · 2025-01-13
Indexed literature (PubMed)12
Sharif S et al. · Brain Sci · 2021
Stefani A et al. · Neurotherapeutics · 2021
Plumber N et al. · Cureus · 2021
Snyder J et al. · Prim Care · 2025
Iglseder B · Z Gerontol Geriatr · 2018
Helbert S et al. · Rev Infirm · 2024
DuPont RL · Pediatr Ann · 2006
Roberts CA et al. · Eur Neuropsychopharmacol · 2020
Johnson J et al. · J Pain Palliat Care Pharmacother · 2016
Schifano F et al. · Biology (Basel) · 2025
Franke AG et al. · Eur Arch Psychiatry Clin Neurosci · 2014
DuPont RL et al. · J Addict Dis · 2007
Keep reading